Cognition Therapeutics, Inc. presented comprehensive results from its Phase 2 COG1201 SHIMMER study in dementia with Lewy bodies (DLB) and the Phase 2 COG0201 SHINE study in Alzheimer’s disease at the Alzheimer’s Association International Conference (AAIC 2025). The SHIMMER study met its primary endpoint of safety and tolerability, showing positive impact across neuropsychiatric, cognitive, motor, and functional scales.
DLB patients treated with zervimesine scored an average of 86% better than placebo-treated patients on the neuropsychiatric inventory (NPI-12), with notable improvements in hallucinations, delusions, and anxiety. These behavioral symptoms are particularly challenging to treat in DLB, making zervimesine’s impact significant.
Results from the SHINE study in Alzheimer’s disease further highlighted zervimesine’s efficacy, arresting cognitive deterioration by 129% in mild AD and 91% in moderate AD in the low p-tau217 subgroup. Biomarker evidence presented also showed zervimesine's effect on proteins involved in neuroinflammation, synapse health, and neurodegeneration, supporting its impact on underlying disease biology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.